1 week ago Natco Pharma Q2: Stock Correction Warrants Dolat Capital's 'Add' Upgrade

With the recent stock correction, Dolat Capital believes there is an upside and upgrade rating to 'Accumulate' from Sell.

Events

2 w. ago Motilal Oswal Maintains 'Buy' On Piramal Pharma Despite Near

Motilal Oswal maintains a 'Buy' rating on Piramal Pharma and revises target price, implying a 20% upside.

Politics

2 w. ago NCC Q2 Review: Execution Delays Drag Performance, Says IDBI Capital Maintaining Buy

IDBI Capital maintains a 'BUY' rating on NCC and revises target price, valuing the stock at 12x FY27E EPS.

Politics

2 w. ago Indigo Paints Q2 Review: ICICI Securities Cuts Target Price Despite Maintaining 'Add' Rating

ICICI Securities has revised the target price downward, while maintaining an 'Add' stance, implying a 14% upside.

Events

2 w. ago Harsha Engineers Shares Upgraded To 'Buy' By IDBI Capital Post Good Q2 Numbers, Sees 20% Upside

IDBI Capital upgrades Harsha Engineers rating from Hold to Buy and revises target price on the back of improved visibility for profitability in key overseas subsidiaries.

Politics

2 w. ago Motilal Oswal Downgrades Updater Services To 'Neutral' Amid Guidance Cuts, Near

Motilal Oswal downgrades Updater to Neutral and revises target price, as weaker BSS trends, lower overall guidance, margin pressures from client issues, ramp-up costs limit near-term visibility.

Politics

2 w. ago Jefferies Keeps Mankind Pharma Among Top Picks Despite Q2 Setback

Jefferies has trimmed the target price of Mankind Pharma citing a slower-than-expected recovery in its reorganisation efforts.

Politics

2 w. ago Paytm Q2 Review: Yes Securities Maintains 'Add', Revises Target Price

Paytm's profitability metrics have improved to some extent, says Yes Securities, sees 10% upside potential.

Economics

2 w. ago Paytm Q2 Review: Strong Growth, New Businesses And AI Push Impress Analysts

Jefferies has the most optimistic view, raising its target price to Rs 1,600 from Rs 1,420, citing strong revenue momentum and expanding financial services.

Economics

4 w. ago 'Sell' Sagar Cements Shares Maintains Dolat Capital Post Muted Q2 Results, Revises Target Price

Dolat Capital maintains 'Sell' rating on Sagar Cements with revised target price based on 7.0x consolidated FY28E EV/Ebitda.

Events